Repros Therapeutics Q3 Loss Widens

(RTTNews) - Repros Therapeutics Inc.(RPRX) posted third-quarter net loss of $6.0 million, wider than $4.6 million in the comparable quarter last year. Loss per share for the latest third quarter was $0.26 per share, narrower than $0.30 per share in the prior year quarter.

On average, five analysts polled by Thomson Reuters expected the company to report a loss of $0.32 per share for the quarter. Analysts' estimates typically exclude special items.

The increase in loss for the three months ended September 30, 2013 as compared to the same period in 2012 was primarily due to an increase in expenses related to the clinical development of Androxal, an increase in salary expense due to increased headcount and increased costs associated with our patent portfolio.

Total revenues and other income for the quarter were $3 thousand, compared to $1 thousand in the year-ago period.